Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN, Ohio, April 13, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the storage and distribution of 80,000 pallets of personal protective equipment (PPE) to support the Strategic National Stockpile (SNS), part of the Office of the Assistant Secretary for Preparedness and Response within HHS. "Cardinal Health is uniquely positioned to get critical products to healthcare providers and first responders as effectively, safely, and swiftly as possible in response to the COVID-19 pandemic," said Steve Mason, CEO Medical Segment.

Cardinal Health awarded Strategic National Stockpile contract for PPE storage and distribution

Con Ed

Johnson & Johnson

Coca-Cola

PepsiCo

Procter & Gamble

AT&T

Unilever

Vanguard High Dividend Yield ETF

Verizon

My dividend stock portfolio was burnt by dividend cuts in 2020 and lost over $800+ in forward dividend income. Therefore, I was ready to get back to basics and acquire more shares in the best quality dividend stocks out there. In total, my dividend stock purchases of VYM totaled $1,485.08, acquiring 15 total shares. This added $45 in forward dividend income.

Dividend Stock Purchase: Lanny's March 2021 Summary

Cardinal Health Inc. makes an attractive 11-15% annual free cash flow yield. The company offers high investor safety with a strong balance sheet, leading industry position, and Dividend Aristocrat status.

Cardinal Health: Exciting Opportunity In A Boring Industry

Cardinal Health (CAH) Specialty Solutions' newly launched Navista TS will help community oncologists to improve patient care and become successful in value-based care while reducing costs.

Cardinal Health (CAH) Unveils Navista TS to Boost Patient Care

DUBLIN, Ohio, April 7, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) Specialty Solutions today launched Cardinal Health™ Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve outcomes and costs associated with patient treatment as they transition to value-based care.  "Community-based oncology practices are facing unprecedented pressure as they pivot to adapt to value-based reimbursement models," said Heidi Hunter, President of Cardinal Health Specialty Solutions.

Cardinal Health Launches Navista™ TS to Help Oncology Practices Improve Patient Care, Lower Costs and Drive Success in Value-Based Care

Sysco

Union Pacific

You can't stop it, but you can give yourself a chance of keeping up with inflation.

Worried About Inflation? These 3 Stocks Can Help

DUBLIN, Ohio, March 30, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2021 on May 6 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Webcast Discussion of Third-Quarter Results for Fiscal Year 2021 on May 6

Cardinal Health may be recovering from its opioid crisis setback in investor demand and valuation. Under normal operating circumstances, Wall Street would be valuing the stock at a price north of $100 currently.

Cardinal Health: Where Rising Price Meets A Bargain Valuation

Amgen

Bayer AG

CVS Health

Gilead Sciences

General Mills

Henkel AG & Co KGaA

Novo Nordisk

Reckitt Benckiser Group PLC

Walgreens

In the following article, I present 10 recession-proof stocks that are undervalued right now. Including companies from the healthcare sector like Gilead Sciences, Amgen, Novo Nordisk, Walgreens Boots Alliance, CVS Health, Cardinal Health and Bayer.

Hunting For Recession-Proof Bargains: 10 Picks As Prey

AbbVie

Chevron

With March almost over, many investors are looking to the second quarter and beyond.

5 High-Yielding Dividend Aristocrat Stocks Are Perfect Now for Worried Investors

Cardinal Health is one of the three major medical distribution companies in the United States. There are a few issues with Cardinal Health like the fluctuating net income during the last two decades and the declining margins.

Cardinal Health: A Fair Company At A Wonderful Price

Cardinal Health (CAH) is witnessing an uptrend in its stock price, prompted by robust performance in both Pharmaceutical and Medical segments during the fiscal second quarter.

Cardinal Health (CAH) Hits New 52-week High: What's Driving It?

Abbott Labs

Hologic

Grab these three top stocks - ABT, HOLX and BIO - that continue to show tremendous promise and stand to benefit from the historic stimulus package.

MedTech to Gain From Economic Stimulus Bill: 3 Stocks to Buy

Marathon Petroleum

M&T Bank

NRG Energy

Principal Financial Group

For years, analysts and portfolio managers have anticipated the return of value stocks as the market has moved higher, and for years they have continued to underperform growth stocks.

5 BofA Securities Top Value Stocks to Buy That Also Pay Big Dividends

Cardinal Health (CAH) divests its Cordis business to focus on strategic growth areas.

Cardinal Health (CAH) Inks Deal to Divest Cordis Business

Cardinal Health Inc (NYSE: CAH) has agreed to sell its Cordis business to Hellman & Friedman, a private equity firm, for approximately $1 billion. The deal value includes the buyer's assumption of certain liabilities and the seller's retention of certain working capital accounts.

Cardinal Health To Divest Cordis Business For $1B

Cardinal Health Inc. announced Friday an agreement to sell its minimally invasive cardiovascular technology business Cordis for about $1 billion to Hellman & Friedman. Shares of the pharmaceutical distributor and maker of laboratory products rose 0.5% in premarket trading.

Cardinal Health to sell Cordis business to Hellman & Friedman for $1 billion

DUBLIN, Ohio, March 12, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for approximately $1 billion, which includes buyer's assumption of certain liabilities and seller's retention of certain working capital accounts. The transaction is expected to close in the first half of Cardinal Health's fiscal year 2022, subject to customary closing conditions and regulatory clearances.

Cardinal Health signs definitive agreement to sell its Cordis business to Hellman & Friedman

McKesson

West Pharmaceutical Services

3 Stocks to Capitalize on Promising Dental Supplies Industry

Cardinal Health, Inc. (CAH) CEO Mike Kaufmann Presents at Barclays Global Healthcare Conference (Transcript)

Algonquin Power & Utilities

British American Tobacco

Canadian Natural Resources

Enbridge

Novartis

Pembina Pipeline

People's United Financial

Sanofi

TC Energy

Kiplinger "insights for investors" online first offered this list of 91 "Top Dividend Stocks From Around The World" 7/13/20. Data updated 3/1/21 flagged 14 with yields ripe with future upside.

The 91 Kiplinger 'Top Dividend Stocks On Earth' March Update

Conagra Brands

Kellogg

Kimberly-Clark

Lockheed Martin

Pfizer

Philip Morris

Which dividend stocks should you consider for both 3%+ yields and the potential for appreciation? These nine names come to mind.

News for Cardinal Health Stock (CAH)